Skip to main content

Impacts of plasma microbial lipopolysaccharide translocation on B cell perturbations and anti-CD4 autoantibody production in people with HIV on suppressive antiretroviral therapy



. Up to 20% of people with HIV (PWH) who undergo virologically suppressed antiretroviral therapy (ART) fail to experience complete immune restoration. We recently reported that plasma anti-CD4 IgG (antiCD4IgG) autoantibodies from immune non-responders specifically deplete CD4 + T cells via antibody-dependent cytotoxicity. However, the mechanism of antiCD4IgG production remains unclear.


. Blood samples were collected from 16 healthy individuals and 25 PWH on suppressive ART. IgG subclass, plasma lipopolysaccharide (LPS), and antiCD4IgG levels were measured by ELISA. Gene profiles in B cells were analyzed by microarray and quantitative PCR. Furthermore, a patient-derived antiCD4IgG–producing B cell line was generated and stimulated with LPS in vitro. B cell IgG class switch recombination (CSR) was evaluated in response to LPS in splenic B cells from C57/B6 mice in vitro.


. Increased plasma anti-CD4 IgGs in PWH were predominantly IgG1 and associated with increased plasma LPS levels as well as B cell expression of TLR2, TLR4, and MyD88 mRNA in vivo. Furthermore, LPS stimulation induced antiCD4IgG production in the antiCD4IgG B cell line in vitro. Finally, LPS promoted CSR in vitro.


. Our findings suggest that persistent LPS translocation may promote anti-CD4 autoreactive B cell activation and antiCD4IgG production in PWH on ART, which may contribute to gradual CD4 + T cell depletion. This study suggests that reversing a compromised mucosal barrier could improve ART outcomes in PWH who fail to experience complete immune restoration.


Antiretroviral therapy (ART) is an effective treatment for people with HIV (PWH) that generally results in viral suppression, increased CD4 + T cell counts, and improved immune function. However, approximately 20% of patients on ART do not achieve complete immune restoration, exhibiting persistently low CD4 + T cell counts despite long-term viral suppression; these patients are referred to as immunological non-responders (INRs) [1,2,3]. Compared with immune responders (IRs), INRs have a significantly increased incidence of morbidity and mortality from AIDS-related and non–AIDS-related diseases [4,5,6].

Various factors have been implicated in the incomplete immune restoration seen in INRs, such as older age, delayed ART initiation, low nadir and baseline CD4 + T cell counts, impaired bone marrow hematopoietic or thymic function, reduced thymic output, residual viral replication, abnormal immune activation and inflammation, and lymphoid tissue fibrosis [7,8,9,10,11,12]. Recently, several studies reported the role of autoantibodies in infectious disease severity [13,14,15], and autoimmunity is recognized for its pathogenic impact on infectious diseases in the absence of any clinical autoimmune disease. We previously showed that anti-CD4 IgG (antiCD4IgG) levels were significantly increased in INRs compared with both IRs and healthy volunteers [16]. Furthermore, patient-derived antiCD4IgG induced antibody-dependent cell-mediated cytotoxicity (ADCC) resulting in CD4 + T cell apoptosis in vitro [17], suggesting that inappropriate production of autoreactive IgG results in depletion of CD4 + T cells in INRs. More recently, the effects of anti-CD4 autoantibodies on CD4 + T cell depletion in HIV were revealed by A Lisco, C-S Wong, SL Lage, I Levy, J Brophy, J Lennox, M Manion, MV Anderson, Y Mejia, C Grivas, et al. [18]. Nevertheless, the driver for antiCD4IgG remains unclear.

The administration of bacterial lipopolysaccharide (LPS) can induce autoantibodies and autoimmunity in animals [19, 20]. Thus, we hypothesize that increased B cell activation and autoantibody production is mediated by elevated microbial products in the bloodstream via the impaired gut mucosal integrity in HIV. Consistently, plasma LPS remain elevated in INRs compared with healthy individuals [21]; elevated plasma levels of LPS and enterobacterial DNA are associated with immune nonresponse in PWH on ART [22]; plasma levels of soluble CD14, a marker of microbial translocation, are higher in PWH on ART than in healthy controls [23]; and plasma levels of bacterial LPS are significantly higher in PWH compared with healthy controls and correlate with a less effective response to ART, as indicated by higher T cell activation and decreased CD4 + T cell counts [24]. However, despite the apparent correlation between markers of microbial translocation in the bloodstream and the failure of ART to restore CD4 + T cell counts, the mechanism underlying this relationship remains unclear. Thus, the present study aimed to determine whether the presence of microbial products in the bloodstream directly stimulates anti-CD4 autoantibody production by B cells in PWH who are undergoing ART.

Materials and methods

Human subjects

The study participants included 16 healthy individuals and 25 PWH on suppressive ART for at least 2 years. The inclusion criteria were as follows: (1) men and women aged 18 or older, (2) able and willing to provide informed consent, (3) healthy individuals who self-reported as being HIV-negative, and (4) PWH on ART with a plasma HIV RNA below the limit of detection for at least 24 weeks (a single reading above 500 copies/mL was allowed). The exclusion criteria were as follows: (1) self-reported pregnancy or breast-feeding, (2) recent severe illness such as anemia, (3) need for or use of specific medications (such as antibiotics, systemic immunomodulatory agents, and supraphysiologic doses of steroids (> 10 mg/day)) during the 120 days before enrollment, and (4) any other condition that rendered a person unsuitable for the study or unable to comply with study requirements, as determined by the lead investigator. This study was approved by the Medical University of South Carolina (Pro00020606). All study participants provided signed informed consent. All PWH had at least 2 years of undetectable plasma HIV-1 RNA. The background clinical features of the participants are summarized in Table 1. A cutoff value of 50 ng/mL antiCD4IgG was used to distinguish between high versus low antiCD4IgG groups because 95% of the healthy participants had plasma anti-CD4 IgG levels lower than this value. Thus, PWH on ART were stratified into low and high autoCD4IgG subgroups.

Table 1 Clinical characteristics of study subjects

Enzyme-linked immunosorbent assay

Microtiter plates were coated with either 1 µg/100 µL/well soluble CD4 protein (sCD4, Progenics Tarrytown, NY) or a 1:20 dilution of the 2013–2014 seasonal influenza antigens at 4 °C overnight. After washing, diluted plasma was added to each well and allowed to incubate for 1 h at room temperature. After washing, horseradish peroxidase–labeled goat anti-human IgG, IgM, IgA (KPL, Gaithersburg, MD), or IgG1-4 subtypes (Thermo Fisher Scientific, Waltham, MA) were added to the microtiter wells and incubated at room temperature with gentle shaking for 60 min. Next, the 2,2’-Azino-di(3-ethylbenzthiazoline-6-sulfonate) substrate solution was added to detect binding. Absorbance was measured at 405 nm. All measurements were performed in duplicate, and the values were normalized to a standard curve generated using the human monoclonal anti-CD4 antibody zanolimumab (HuMax-CD4; Genmab) (0.05–10 ng/mL).

Quantitative PCR (qPCR) analysis and microarray of mRNA expression in B cells

B cells were isolated using a negative selection kit (Qiagen, Hilden, Germany). The purity of the isolated cells was always above 96%. TRizol (MRC, UK) was used to isolate total RNA, and cDNA was synthesized by reverse transcription using M-MLV reverse transcriptase (Promega Corporation, Madison, WI, USA) and random primers. The obtained cDNA was diluted at 1:25 with water, and 10 µL of the diluted solutions were used as the template for the amplification step. Parameter-specific primer sets optimized for the LightCycler (RAS) were developed by and purchased from Search-LC (Heidelberg, Germany); the primer sequences were described previously [25]. The PCR reaction was performed using a LightCycler FastStart DNA SYBR Green I kit (RAS), with conditions specified by the primer manufacturer. The method of microarray analysis was described in our previous studies [26]. Briefly, total RNA was extracted from 2 × 106 B cells using the RNeasy Micro kit (Qiagen), quantitated, qualified with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and run with Affymetrix GeneChip assays. The Affymetrix Human GeneChip U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) was used for RNA hybridization and labeling according to the manufacturer’s protocol. The analysis of the scanned images and signal values for each probe set was obtained with the GCOS (Affymetrix). R program (3.3.1) was used for microarray data analysis.

Measurement of plasma LPS levels

Plasma samples were diluted to 10% in endotoxin-free water and heated at 80 °C for 10 min to inactivate inhibitory plasma proteins. The LPS levels in the diluted plasma samples were then quantified using a Limulus amebocyte lysate QCL-1000 kit (Lonza), as described previously [27].

Generation of a patient-derived anti-CD4 IgG–producing B cell line

PBMCs were obtained from an INR participant who expressed high levels of anti-CD4 IgG by density gradient centrifugation of whole heparinized blood. Sorted B cells were transformed in vitro by culturing in EBV-containing supernatants collected from the B95-8 cell line (ATCC® VR-1492™). The transformed B cells were then seeded at approximately 1000 cells/well in 384-well plates in complete medium containing 3 mg/mL CpG2006 (InvivoGen). After 2 weeks, the culture supernatants were screened for specific antibody production by ELISA. Positive cultures were cloned by limiting dilution in the presence of CpG 2006 and irradiated mononuclear cells.

In vitro B cell stimulation

The patient-derived anti-CD4 B cell line was cultured in complete RPMI medium, consisting of RPMI-1640 supplemented with 15% fetal bovine serum (FBS, vol/vol), 50 µg/mL penicillin/streptomycin, and 1 mM sodium pyruvate. LPS (50 ng/mL, E. coli O55:B5, InvivoGen, San Diego, CA), inactivated Staphylococcus aureus, Pseudomonas aeruginosa, cytomegalovirus (107 CFU/mL), IL-23, or IL-17 (50 ng/mL) was used to stimulate cells for 10 days. Cell culture supernatants were collected for evaluation of cell counts and anti-CD4 IgG production.

B cell class switch DNA recombination (CSR)

B cells were isolated from the spleen of 8- to 10-week-old unmanipulated C57BL/6J mice using the B Cell Negative Isolation Kit (STEMCELL Technologies, Cambridge, MA). B cells were cultured with complete medium and 50 µM of β-mercaptoethanol (Thermo Fisher Scientific) at 5 × 105 cells/mL then treated for 96 h with medium, LPS (3 µg/mL) plus IL-4 (5 ng/mL, Biolegend), IFN-γ (50 ng/mL, BioLegend] or TGF-β1 (2 ng/mL, R&D Systems, Minneapolis, MN). Cells were harvested and stained with Ghost Dye™ Red 780 (TONBO, San Diego, CA). CSR was analyzed by the percentages of proliferating IgG3 and IgG2b cells using a BD FACSVerse™ Cell Analyzer (BD, San Jose, CA) after surface staining with anti-B220 (RA3-6B2), anti-IgG2b (RMG2b-1), anti-IgG3 (R40-82), anti-CD138 (281-2), and anti-IgM (RMM-1) from BioLegend.

Statistical analyses

The non-parametric Mann-Whitney test between two groups and one-way ANOVA with the Kruskal-Wallis test for more than two groups were used to determine differences in continuous measurements. Spearman’s correlation test was used to determine associations. The data were analyzed using GraphPad Prism software Version 8.3.0 (San Diego, CA, USA) and R program (3.3.1); P < 0.05 was considered statistically significant.


Anti-CD4 IgG1 is the predominant subclass in PWH on ART

IgG1 and IgG3 antibodies can induce ADCC, unlike IgG2 and IgG4 [28]. We first investigated anti-CD4 IgM and IgG subclasses in PWH on ART. To address this, we performed an ELISA of plasma samples from all study participants including healthy controls and PWH with high antiCD4IgG or low antiCD4IgG. As expected, anti-CD4 IgM levels were similar in healthy controls and all PWH on ART, regardless of respective anti-CD4 IgG levels (Fig. 1A). In contrast, anti-CD4 IgG1 was the predominant subclass in PWH on ART with high antiCD4IgG levels compared to PWH on ART with low antiCD4IgG levels, while all other subclasses were expressed at similar levels in all groups (Fig. 1B–D). Correlation analysis indicated a significant relationship between antiCD4IgG and anti-CD4 IgG1, as well as, unexpectedly, anti-CD4 IgG3. These results suggest that anti-CD4 IgG1 may be primarily responsible for the effects of anti-CD4 autoantibodies observed in PWH on ART.

Fig. 1
figure 1

Anti-CD4 IgG1 is the predominant subclass in PWH on ART. Plasma levels of anti-CD4 IgM (A), IgG1 (B), IgG2 (C), IgG3 (D), and IgG4 (E) were assessed by ELISA from healthy controls (n = 16), and PWH on ART with high (HIV+/antiCD4high, n = 8) versus low (HIV+/antiCD4low, n = 17) antiCD4IgG levels. ANOVA tests were used to analyze data. (F) Correlations between antiCD4IgG and subclasses. Spearman correlation tests. *, P < 0.05; **, P < 0.01; ****, P < 0.0001

High levels of antiCD4IgGs are associated with increased plasma LPS levels and B-cell TLR4 (not TLR2, TLR7, or TLR9) mRNA expression, and B-cell gene profiles related to microbial translocation

Our previous study showed the link between plasma microbial translocation and autoantibody levels in systemic lupus erythematosus (SLE) autoimmune disease [29]. We speculated that characteristics of B cell gene expression in PWH on ART who present with high levels of antiCD4IgGs may reflect gene profiles related to long-term persistent microbial product translocation in the bloodstream. Therefore, we assessed B cell gene expression profiles by analyzing the mRNA expression of TLR signaling molecules in B cells. We found that PWH on ART with high plasma antiCD4IgG levels had increased TLR4 but similar levels of TLR2, MyD88, TLR7, and TLR9 mRNA expression in B cells compared with PWH on ART with low plasma antiCD4IgG levels (Fig. 2A, Supplementary Fig. 1A). Intriguingly, PWH on ART with low plasma antiCD4IgG levels also exhibited elevated TLR2 expression, but not TLR4 expression, compared with the healthy controls (Fig. 2A). Furthermore, correlation analysis showed that plasma antiCD4IgG levels correlated with IgG1 and IgG3 subclasses, as well as with levels of TLR2, TLR4, and MyD88 mRNA expression in B cells (Fig. 2B). B cell gene microarray analysis showed that several pathways of gene profiles were associated with microbial translocation, autoimmunity, and others in PWH with high versus low antiCD4IgG levels (Fig. 2C). Taken together, these results suggest that anti-CD4 autoreactive B cell activation in PWH on ART likely involves microbial product–mediated signaling pathways such as TLR4 in vivo.

Fig. 2
figure 2

High plasma levels of antiCD4IgG are associated with increased TLR2 and TLR4 expression and distinct cell signaling pathway activation in B cells from PWH on ART. Total mRNA was extracted from B cells isolated from healthy controls (n = 7) and PWH on ART with high (HIV+/antiCD4high, n = 6) versus low (HIV+/antiCD4low, n = 7) anti-CD4 IgG levels. (A) Relative mRNA expression of TLR2, TLR4, TLR7, and TLR9 versus GAPDH in B cells as determined by qPCR. ANOVA tests were used to analyze data. High: antiCD4IgG > 50 ng/mL; Low: antiCD4IgG ≤ 50 ng/mL. (B) Correlations between plasma anti-CD4 autoantibody levels and TLR and MyD88 mRNA expression in B cells. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. (C) The representative immunological pathways were enriched in coherently changed genes between the two HIV groups

Plasma LPS, a marker of microbial translocation, stimulates autoantibody production in an antiCD4IgG producing B cell line in vitro.

The elevated TLR2 and TLR4 expression observed in B cells from the high antiCD4IgG PWH group suggested innate immune activation via TLR2 and TLR4 in these patients in response to microbial products (e.g., bacterial LPS). Therefore, we evaluated plasma levels of LPS, a marker of systemic microbial translocation. Anti-influenza IgG was assessed as a control, as all subjects had received the seasonal influenza vaccine in the preceding year. We found that LPS levels increased in the PWH group with high antiCD4IgG levels versus healthy controls, and marginally increased in the high antiCD4IgG group versus the low antiCD4IgG group (Fig. 3A). There was a direct correlation between plasma LPS and antiCD4IgG levels in all subjects tested (Fig. 3A); however, the correlation was mainly driven by the subjects with high anti-CD4 IgG levels but not the subjects with low anti-CD4 IgG levels; furthermore, r = 0.37 is a weak correlation (Fig. 3A). This correlation was not detected between plasma LPS and anti-influenza IgG (Supplementary Fig. 1B). Given the observed correlation between the plasma LPS levels and antiCD4IgG levels, we investigated whether a causal relationship existed. To test this, we generated an antiCD4IgG–producing B cell line from one non-responder study participant and stimulated those cells with LPS, whole inactivated S. aureus, P. aeruginosa, CMV, IL-23, or IL-17 (two cytokines related to microbe-induced mucosal inflammation) for 10 days in vitro. Whole bacteria and CMV virus were used as controls. We found that stimulation with IL-17 significantly increased cell counts at the end of the culturing period, while stimulation with LPS tended to increase cell counts but did not achieve statistical significance (Fig. 3B). Furthermore, LPS increased antiCD4IgG production, unlike any of the other stimuli (Fig. 3C). Taken together, these findings suggest that elevated IL-17 levels associated with mucosal inflammation promote B cell proliferation, and LPS may contribute to autoreactive B cell activation and production of antiCD4IgG in PWH on ART.

Fig. 3
figure 3

LPS correlated with antiCD4IgG production in vivo and stimulated antiCD4IgG production by B cells in vitro. Plasma LPS levels in healthy controls and virologically suppressed PWH on ART who presented with high versus low antiCD4IgG levels were evaluated by LAL assay. (A) Plasma LPS levels in the three study groups. Correlation between antiCD4IgG and LPS levels. B cell counts (B) and proliferation (C) in response to LPS, S. aureus, P. aeruginosa, CMV, IL-23, or IL-17 in a patient-derived antiCD4IgG-producing B cell line. ANOVA and Spearman correlation tests were used to analyze data

LPS drives CSR

CSR is a crucial biological process for antibody maturation in response to both foreign antigens and self-antigens in the germinal center [30]. To investigate the mechanism of LPS-mediated autoantibody production, we culture mouse splenic B cells with LPS and cytokines related to CSR in mice. B cells were isolated from C57BL/6J mice and cultured with medium, LPS (3 µg/mL) plus IL-4 (5 ng/mL), IFN-γ (50 ng/mL), or TGF-β1 (2 ng/mL) for 96 h. The percentages of proliferating IgG subclass B cells in total B cells (%CFSElowIgG1/2a/2b/IgG3 + in B220 + cells) were evaluated for CSR. LPS plus cytokines promoted IgG CSR to IgG1, 2a, 2b, and 3, but LPS alone had the limited ability to drive CSR in vitro (Fig. 4 and Supplementary Fig. 2). These results are consistent with previous studies [31, 32].

Fig. 4
figure 4

LPS promotes IgG class switch recombination in vitro. B cells were isolated from C57BL/6J mice and cultured with medium, LPS (3 µg/mL) plus IL-4 (5 ng/mL), IFN-γ (50 ng/mL), or TGF-β1 (2 ng/mL) for 96 h. Shown are the representative dot plots and summarized percentages of proliferating IgG subclass B cells in total B cells (%CFSElowIgG1/2a/2b/IgG3 + in B220 + cells). Non-parametric Mann-Whitney tests were used to analyze data


Autoimmunity plays a pathogenic role in infectious diseases in the absence of any clinical autoimmune disease [13,14,15]. In this study, we found that elevated plasma microbial LPS translocation was associated with B cell activation and antiCD4IgG production in PWH on ART. Furthermore, stimulation of LPS induced antiCD4IgG production in a patient-derived B cell line, and CSR in isolated splenic B cells from C57/B6 mice in vitro. Taken together, our findings suggest that a comprised mucosal barrier and systemic microbial product translocation may induce B cell activation and anti-CD4 autoantibody production in some PWH on ART, resulting in failure of immune restoration (Fig. 5).

Fig. 5
figure 5

A model is proposed for increased plasma microbial product translocation–mediated B cell activation and anti-CD4 pathogenic autoantibody production leading to decreased CD4 + T cell counts in virologically suppressed PWH on ART. In our model, elevated plasma levels of LPS due to impaired mucosal barriers repeatedly stimulated the immune system resulting in increased TLR2 and TLR4 expression in B cells, with different one-time effects and high dose effects. The anti-CD4IgG–producing B cells then produced antiCD4IgGs in response to CD4 or HIV gp120-CD4. The resulting high plasma levels of antiCD4IgG induced CD4 + T cell death through ADCC, leading to the failure of immune reconstitution despite viral suppression with ART.

Consistent with previously published studies, we found that plasma antiCD4IgG levels remained elevated in PWH on ART, even though levels of other HIV infection-associated autoantibodies decreased following ART [16, 33, 34]. HIV infection prior to ART is associated with polyclonal autoreactive B cell activation and the production of various IgG autoantibodies, including antiCD4IgG, suggesting nonfunctional autoantibodies with low affinity mediated by chronic inflammation [27, 35,36,37,38]. In contrast, antiCD4IgGs generated during suppressive ART can be pathogenic, mediate CD4 + T cell death via ADCC, and play a role in poor CD4 + T cell recovery after ART [16, 18, 39, 40]. Anti-CD4 IgG1 is the predominant subclass in PWH, which is consistent with its ADCC activity [16, 40].

While earlier studies have reported autoreactive B cell activation in untreated PWH, here we show activation of B cells in PWH on ART. The innate immune pathway activation is consistent with elevated plasma LPS observed in PWH on ART who have high levels of antiCD4IgG compared with healthy controls [41]. Similarly, RF Tanko, AP Soares, TL Müller, NJ Garrett, N Samsunder, Q Abdool Karim, SS Abdool Karim, C Riou and WA Burgers [42] reported that perturbations of B cell profiles largely normalized in PWH after 12 months on ART, but B cell activation remained high and was positively associated with plasma sCD14 levels [42]. Our findings show that this B cell activation specifically involves the upregulation of components of signaling pathways related to microbial products.

We further found that in vitro stimulation of LPS promoted antiCD4IgG production in patient-derived antiCD4IgG-producing B cells, likely due to increased TLR4 expression, a main receptor for LPS. This is unexpected, given that B cells from healthy humans generally do not express TLR4 and do not respond to LPS stimulation [43, 44]. In previous studies, short-term high dose of LPS stimulation may result in TLR4 downregulation in cells in vitro [45,46,47] but conflict results were also reported [48, 49]. Nonetheless, the effect of long-term low dose of LPS repeated stimulation on TLR4 remains unknown. This in vitro finding, in combination with the correlation that we observed between plasma LPS levels and antiCD4IgG levels in PWH on ART, implies that increased TLR4 expression may be functional and mainly on autoreactive B cells which result in the atypical autoreactive B cell activation and autoantibody production due to persistent microbial LPS translocation. Indeed, the increased TLR4 expression on CD8 + T cells has been found in patients with Rheumatoid Arthritis (RA) and responded to LPS to produce inflammatory cytokines; these CD8 + T cells contributed to inflammation and RA disease pathogenesis [50]. Besides autoimmunity, it remains unknown whether the increased TLR4 expression accounts for the LPS-sensitizing controls of infection.

In general, a “leaky” barrier and increased microbial product translocation (e.g., inflammatory bowel disease) associate with increased various autoantibodies in the absence of pathogenic activities [51, 52]. However, in individuals with a genetic predisposition or with immune perturbations (e.g., HIV), bacterial products (e.g., LPS) may enter the body via a leaky gut and trigger the development of pathogenic autoantibody production with or without clinical autoimmune diseases [53]. Moreover, the dose of LPS used the in vitro assay was much higher than those in the plasma. We assume that anti-CD4 IgG-producing B cells are activated and anti-CD4 IgGs are produced in the gut lymph nodes but not in the circulation in vivo. Thus, the LPS concentration is expected much higher in the gut lymph nodes compared to the blood. Thus, autoreactive B cells in the gut lymph nodes may be activated to produce autoantibodies in response to a high concentration of LPS. Finally, whether sorted antigen-specific B cells or IgG + or IgM + B cells respond to LPS directly deserves further investigations.

In conclusion, our study provides strong evidence that the mechanism underlying the failure of immune restoration in INRs involves microbial translocation into the bloodstream and, subsequently, LPS–mediated B cell activation and production of antiCD4IgGs that specifically deplete the CD4 + T cell population. This suggests that reversing a compromised mucosal barrier could improve ART outcomes in PWH who fail to experience complete immune restoration.

Data Availability

Data are available upon request.



antibody-dependent cell-mediated cytotoxicity


antiretroviral therapy


immunological nonresponder


immune responder


people living with HIV


quantitative PCR


  1. World Health Organization. : UNAIDS:Global HIV & AIDS Statistics; 2020.

  2. Rb-Silva R, Nobrega C, Azevedo C, Athayde E, Canto-Gomes J, Ferreira I, Cheynier R, Yates AJ, Horta A, Correia-Neves M. Thymic function as a predictor of immune recovery in chronically HIV-infected patients initiating antiretroviral therapy. Front Immunol. 2019;10:25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-saharan Africa. AIDS. 2018;32(8):1043–51.

    Article  PubMed  Google Scholar 

  4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected adults and adolescents. Department of Health and Human Services; 2013.

  5. Shete A, Dhayarkar S, Sangale S, Medhe U, Panchal N, Rahane G, Yelgate R, Dhamanage A, Gangakhedkar R. Incomplete functional T-cell reconstitution in immunological non-responders at one year after initiation of antiretroviral therapy possibly predisposes them to infectious diseases. Int J Infect Dis. 2019;81:114–22.

    Article  CAS  PubMed  Google Scholar 

  6. Stiksrud B, Aass HCD, Lorvik KB, Ueland T, Trøseid M, Dyrhol-Riise AM. Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4 + recovery. AIDS. 2019;33(7):1117–29.

    Article  CAS  PubMed  Google Scholar 

  7. Negredo E, Massanella M, Puig J, Pérez-Álvarez N, Gallego‐Escuredo José M, Villarroya J, Villarroya F, Moltó J, Santos José R, Clotet B, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV‐infected patients: clinical implications. Clin Infect Dis. 2010;50(9):1300–8.

    Article  PubMed  Google Scholar 

  8. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno C-F, Monforte AdA, Galli M, Meroni L. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS. 2006;20(13):1727–36.

    Article  PubMed  Google Scholar 

  9. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15(14):1749–56.

    Article  CAS  PubMed  Google Scholar 

  10. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4 + T cell gains in human immunodeficiency virus–infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187(10):1534–43.

    Article  CAS  PubMed  Google Scholar 

  11. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects. JAIDS J Acquired Immune Defic Syndr. 2006;42(4):426–34.

    Article  CAS  Google Scholar 

  12. Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub Timothy E, Davenport M, Crowe S, Elliott J, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis. 2010;202(8):1254–64.

    Article  CAS  PubMed  Google Scholar 

  13. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Beziat V et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020, 370(6515).

  14. Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D. With the Amsterdam UMCC-BI: autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;47(6):704–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022;119(21):e2200413119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Luo Z, Li Z, Martin L, Wan Z, Meissner EG, Espinosa E, Wu H, Yu X, Fu P, Julia Westerink MA, et al. Pathological role of anti-CD4 antibodies in HIV-infected immunologic nonresponders receiving virus-suppressive antiretroviral therapy. J Infect Dis. 2017;216(1):82–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Luo Z, Li Z, Martin L, Hu Z, Wu H, Wan Z, Kilby M, Heath SL, Huang L, Jiang W. Increased natural killer cell activation in HIV-infected immunologic non-responders correlates with CD4 + T cell recovery after antiretroviral therapy and viral suppression. PLoS ONE. 2017;12(1):e0167640.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lisco A, Wong C-S, Lage SL, Levy I, Brophy J, Lennox J, Manion M, Anderson MV, Mejia Y, Grivas C, et al. Identification of rare HIV-1-infected patients with extreme CD4 + T cell decline despite ART-mediated viral suppression. JCI Insight. 2019;4(8):e127113.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Izui S, Kobayakawa T, Louis J, Lambert PH. Induction of thymocytotoxic autoantibodies after injection of bacterial lipopolysaccharides in mice. Eur J Immunol. 1979;9(4):338–41.

    Article  CAS  PubMed  Google Scholar 

  20. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol. 2005;167(1):47–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Caaveiro JMM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. Immunol Rev. 2015;268(1):201–21.

    Article  CAS  PubMed  Google Scholar 

  22. Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AdA. Microbial translocation is associated with sustained failure in CD4 + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035–8.

    Article  CAS  PubMed  Google Scholar 

  23. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, Wanke CA, Ward HD. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211(1):19–27.

    Article  CAS  PubMed  Google Scholar 

  24. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection [Erratum in J Infect Dis. 2009 Jul 1;200(1):160]. J Infect Dis 2009, 199(8):1177–1185.

  25. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531–7.

    Article  CAS  PubMed  Google Scholar 

  26. Luo Z, Li M, Mi F, Meng Z, Du G, Martin L, Liu H, Jin P, Stroncek D, Heath SL et al. A link between IL-23 and anti-CD4 autoantibody production in antiretroviral-treated HIV-infected individuals.J Virol2021.

  27. Lartigue A, Colliou N, Calbo S, François A, Jacquot S, Arnoult C, Tron F, Gilbert D, Musette P. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol. 2009;183(10):6207–16.

    Article  CAS  PubMed  Google Scholar 

  28. Rozsnyay Z, Sarmay G, Walker M, Maslanka K, Valasek Z, Jefferis R, Gergely J. Distinctive role of IgG1 and IgG3 isotypes in fc gamma R-mediated functions. Immunology. 1989;66(4):491–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Ogunrinde E, Zhou Z, Luo Z, Alekseyenko A, Li QZ, Macedo D, Kamen DL, Oates JC, Gilkeson GS, Jiang W. A link between plasma Microbial Translocation, Microbiome, and Autoantibody Development in First-Degree relatives of systemic Lupus Erythematosus Patients. Arthritis & rheumatology. 2019;71(11):1858–68.

    Article  CAS  Google Scholar 

  30. Mietzner B, Tsuiji M, Scheid J, Velinzon K, Tiller T, Abraham K, Gonzalez JB, Pascual V, Stichweh D, Wardemann H, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A. 2008;105(28):9727–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ning W, Cheng D, Howe PH, Bian C, Kamen DL, Luo Z, Fu X, Ogunrinde E, Yang L, Wang X, et al. Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus. J Autoimmun. 2022;131:102860.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Snapper CM, Waegell W, Beernink H, Dasch JR. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J Immunol. 1993;151(9):4625–36.

    Article  CAS  PubMed  Google Scholar 

  33. Song A, Li Z, Luo Z, Lu X, Wang R, Liu L, Xia W, Wan Z, Zhang T, Su B, et al. Effects of Early and delayed antiretroviral therapy on plasma Anti-CD4 autoreactive IgG and its Association with CD4(+) T-Cell recovery in Acute HIV-Infected individuals. Front Pharmacol. 2020;11:449.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bowler S, Mitchell BI, Kallianpur KJ, Chow D, Jiang W, Shikuma CM, Ndhlovu LC. Plasma anti-CD4 IgG is associated with brain abnormalities in people with HIV on antiretroviral therapy. J Neurovirol 2021.

  35. Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, Zinkernagel RM. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol. 2003;4(4):343–9.

    Article  CAS  PubMed  Google Scholar 

  36. Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH, Wiedeman AE, Kim J, Tanaka L, Buechler MB, Hamerman JA, et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med. 2013;210(12):2773–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kolhatkar NS, Brahmandam A, Thouvenel CD, Becker-Herman S, Jacobs HM, Schwartz MA, Allenspach EJ, Khim S, Panigrahi AK, Luning Prak ET, et al. Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. J Exp Med. 2015;212(10):1663–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cain D, Kondo M, Chen H, Kelsoe G. Effects of acute and chronic inflammation on B-cell development and differentiation. J Invest Dermatol. 2009;129(2):266–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Perez-Diez A, Wong C-S, Liu X, Mystakelis H, Song J, Lu Y, Sheikh V, Bourgeois JS, Lisco A, Laidlaw E, et al. Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia. J Clin Invest. 2020;130(10):5326–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jiang W, Luo Z, Martin L, Wan Z, Fu P, Wagner A, Ling B, Heath SL, Haque A, McRae-Clark A. Drug use is associated with anti-CD4 IgG-mediated CD4 + T cell death and poor CD4 + T cell recovery in viral-suppressive HIV-infected individuals under antiretroviral therapy. Curr HIV Res. 2018;16(2):143–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Xu W, Luo Z, Alekseyenko AV, Martin L, Wan Z, Ling B, Qin Z, Heath SL, Maas K, Cong X, et al. Distinct systemic microbiome and microbial translocation are associated with plasma level of anti-CD4 autoantibody in HIV infection. Sci Rep. 2018;8(1):12863.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Tanko RF, Soares AP, Müller TL, Garrett NJ, Samsunder N, Abdool Karim Q, Abdool Karim SS, Riou C, Burgers WA. Effect of antiretroviral therapy on the memory and activation profiles of B cells in HIV-infected african women. J Immunol. 2017;198(3):1220–8.

    Article  CAS  PubMed  Google Scholar 

  43. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang Z-y, Seaton KE, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239.

    Article  Google Scholar 

  44. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, Niewold TB, Tsokos GC, Keith MP, Harley JB, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014–21.

    Article  CAS  PubMed  Google Scholar 

  45. Wu C, Liu C, Luo K, Li Y, Jiang J, Yan F. Changes in expression of the membrane receptors CD14, MHC-II, SR-A, and TLR4 in tissue-specific Monocytes/Macrophages following Porphyromonas gingivalis-LPS stimulation. Inflammation. 2018;41(2):418–31.

    Article  CAS  PubMed  Google Scholar 

  46. Ghosh AK, Sinha D, Mukherjee S, Biswas R, Biswas T. LPS stimulates and Hsp70 down-regulates TLR4 to orchestrate differential cytokine response of culture-differentiated innate memory CD8(+) T cells. Cytokine. 2015;73(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  47. Karimi MH, Barzkar Z, Babaee M, Naghdi M. Evaluating effect of mesenchymal stem cells on expression of TLR2 and TLR4 in mouse DCs. Adv Pharm Bull. 2016;6(2):179–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zheng W, Zheng X, Liu S, Ouyang H, Levitt RC, Candiotti KA, Hao S. TNFalpha and IL-1beta are mediated by both TLR4 and Nod1 pathways in the cultured HAPI cells stimulated by LPS. Biochem Biophys Res Commun. 2012;420(4):762–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Al-Aalim AM, Al-Iedani AA, Hamad MA. Study of the effects of Escherichia coli lipopolysaccharide on innate immunity: the expression profile of TLR4 and CD14 genes in rat liver. Open Vet J. 2021;11(4):771–9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Tripathy A, Khanna S, Padhan P, Smita S, Raghav S, Gupta B. Direct recognition of LPS drive TLR4 expressing CD8(+) T cell activation in patients with rheumatoid arthritis. Sci Rep. 2017;7(1):933.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Duryee MJ, Ahmad R, Eichele DD, Hunter CD, Mitra A, Talmon GA, Singh S, Smith LM, Rosen MJ, Dhawan P, et al. Identification of Immunoglobulin G Autoantibody against Malondialdehyde-Acetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13(4):e00469.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Rydell N, Ekoff H, Hellstrom PM, Moverare R. Measurement of Serum IgG Anti-Integrin alphavbeta6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med 2022, 11(7).

  53. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a Danger Signal for Autoimmune Diseases. Front Immunol. 2017;8:598.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


This work was supported by the Ralph H. Johnson VA Medical Center (CX002422, Jiang) Merit Review Award Number from the United States (U.S.) Department of Veterans Affairs Office of Research and Development (CSR&D) Service, and Department of Veterans Affairs Office of Research, Development (CSR&D) Service, the VA Southeast Network 7 Research Development Award (RDA, Adekunle), the National Institutes on Drug Abuse R01DA055523 (Jiang), R03DA057164 (Jiang), National Institutes of Health/National Center for Advancing Translational Sciences NIH/NCATS grant UL1TR001450, TL1TR002382 (Adekunle), UL1TR002378 (TL1 grant, Adekunle), AI128864, and P30 AI027767 (Saag/Health). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations



Z.L., D.S., and W.J. conceived and directed the project. X.F. wrote the manuscript. Z.L., L.M., H.L., P.G., A.R., and X.F. performed the experiments. W.J., Z.S., and J.E.M critically reviewed the manuscript. We thank John Dr. Dinolfo, Ph.D. from MUSC for English Language editing. All authors read and approved the manuscript and consented to its publication.

Corresponding author

Correspondence to Wei Jiang.

Ethics declarations

Ethical approval

The study was approved by the Institutional Review Board (IRB) at the Medical University of South Carolina and the IRB at the University of Alabama at Birmingham. Informed consent was obtained from all study participants.

Conflicts of interest

The authors have no financial conflicts of interest.

Accession numbers

Microarray data are available in GEO (Gene Expression Omnibus, with the accession number GSE109837.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, X., Cheng, D., Luo, Z. et al. Impacts of plasma microbial lipopolysaccharide translocation on B cell perturbations and anti-CD4 autoantibody production in people with HIV on suppressive antiretroviral therapy. Cell Biosci 13, 78 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: